Pictor, a proteomics-focused company, closed a $7.5 million bridge funding round to expand commercial partnerships, scale its platform development, and support translational studies. The company said the capital will be directed toward manufacturing capacity and extending partnerships that use its platform. Bridge rounds often signal an inflection point in platform commercialization or the need to fund translational work ahead of larger financings. For the proteomics sector, additional runway can accelerate method adoption and support downstream applications in drug development. The round also fits a broader pattern of continued investor interest in enabling technologies positioned to improve discovery throughput and translational readiness.